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Examining variations in prescribing safety in UK general practice: 
cross sectional study using the Clinical Practice Research Datalink
S Jill Stocks,1 Evangelos Kontopantelis,2,3 Artur Akbarov,3 Sarah Rodgers,4 Anthony J Avery,4  
Darren M Ashcroft1,5 
ABSTRACT
Study queStion
What is the prevalence of different types of potentially 
hazardous prescribing in general practice in the 
United Kingdom, and what is the variation between 
practices?
MethodS
A cross sectional study included all adult patients 
potentially at risk of a prescribing or monitoring error 
defined by a combination of diagnoses and 
prescriptions in 526 general practices contributing to 
the Clinical Practice Research Datalink (CPRD) up to 1 
April 2013. Primary outcomes were the prevalence of 
potentially hazardous prescriptions of anticoagulants, 
anti-platelets, NSAIDs, β blockers, glitazones, 
metformin, digoxin, antipsychotics, combined 
hormonal contraceptives, and oestrogens and 
monitoring by blood test less frequently than 
recommended for patients with repeated prescriptions 
of angiotensin converting enzyme inhibitors and loop 
diuretics, amiodarone, methotrexate, lithium, or 
warfarin.
Study anSwer and liMitationS
49 927 of 949 552 patients at risk triggered at least one 
prescribing indicator (5.26%, 95% confidence interval 
5.21% to 5.30%) and 21 501 of 182 721 (11.8%, 11.6% to 
11.9%) triggered at least one monitoring indicator. The 
prevalence of different types of potentially hazardous 
prescribing ranged from almost zero to 10.2%, and for 
inadequate monitoring ranged from 10.4% to 41.9%. 
Older patients and those prescribed multiple repeat 
medications had significantly higher risks of triggering 
a prescribing indicator whereas younger patients with 
fewer repeat prescriptions had significantly higher risk 
of triggering a monitoring indicator. There was high 
variation between practices for some indicators. 
Though prescribing safety indicators describe 
prescribing patterns that can increase the risk of harm 
to the patient and should generally be avoided, there 
will always be exceptions where the indicator is 
clinically justified. Furthermore there is the possibility 
that some information is not captured by CPRD for 
some practices—for example, INR results in patients 
receiving warfarin.
what thiS Study addS
The high prevalence for certain indicators emphasises 
existing prescribing risks and the need for their 
appropriate consideration within primary care, 
particularly for older patients and those taking 
multiple medications. The high variation between 
practices indicates potential for improvement through 
targeted practice level intervention.
Funding, CoMpeting intereStS, data Sharing 
National Institute for Health Research through the 
Greater Manchester Primary Care Patient Safety 
Translational Research Centre (grant No 
GMPSTRC-2012-1). Data from CPRD cannot be shared 
because of licensing restrictions.
Introduction
Prescribing errors in primary care can cause consider-
able harm, with adverse drug events accounting for 
around 7% of hospital admissions in the United King-
dom, and half of these are judged to be preventable.1-3 
In 2012 the Practice Study found that one in 20 prescrip-
tion items was associated with a clinically important 
error and one in 550 was associated with a serious 
error.4 Prescribing safety indicators (indicators) define 
prescribing patterns that can increase the risk of harm 
to the patient and should generally be avoided, though 
there will always be exceptions where the indicator is 
justified for clinical reasons.
Several sets of indicators have been developed for 
use in primary care in the UK.5-10  The widespread use of 
electronic prescribing systems and primary care patient 
records facilitates the analysis of aggregate patient 
records to estimate the prevalence of indicators and 
their variation in prevalence between practices and to 
examine the patient and practice factors that influence 
their occurrence. In Scotland, a set of indicators was 
developed through consensus between GPs and 
 pharmacists and their prevalence was measured in 315 
general practices.9 In England, a pharmacist led 
 intervention was found to reduce the frequency of indi-
cators in general practice (PINCER trial),10  while in 
WhAT IS AlReAdy knoWn on ThIS TopIC
Prescribing safety indicators have been developed to identify patients at increased 
risk of hazardous prescribing in primary care
Although these prescribing safety indicators have been investigated in 
experimental settings, they have not been assessed in a large UK-wide primary care 
database
WhAT ThIS STudy AddS
Variation in the prevalence of potentially high risk prescribing and lack of 
appropriate monitoring tests between practices was high, even after adjustment for 
patient and practice level variables, pointing towards important targets for 
improving patient safety in primary care
In a broadly representative sample of 526 UK general practices, about 5% of 
patients at risk were found to have received a potentially inappropriate prescription 
and about 12% had no record of appropriate monitoring
Older patients and those receiving multiple repeat prescriptions had the highest 
risk of triggering a prescribing safety indicator, whereas younger patients with fewer 
repeat prescriptions had higher risk of triggering a monitoring indicator
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Scotland, validated measures of high risk prescribing 
were the outcome measures in a trial of an intervention 
to reduce high risk prescribing of non-steroidal anti-in-
flammatory drugs (NSAIDs) and antiplatelet agents in 
general practice.11  The set of indicators used for the 
PINCER trial was developed through consensus among 
GPs8  and has been expanded and made available for 
GPs to use as an audit tool since 2013.8 10 12 13  Currently 
GPs in the UK are encouraged to report clinical audit or 
quality improvement projects as part of their revalida-
tion portfolio.14
If these indicators are to be used by GPs as an audit 
tool there needs to be an agreement about what consti-
tutes a clinically acceptable prevalence of high risk pre-
scribing and whether there are potential exceptions. 
Furthermore, the ability of indicators to discriminate 
between practices and the relation between their prev-
alence and patient and/or practice characteristics 
needs to be understood; identifying groups of patients 
at increased risk of indicators will enable a targeted 
approach to reducing their occurrence. As far as we 
know, indicators have not been investigated in a large 
sample of UK-wide general practices.
We used anonymised patient level data from the 
Clinical Practice Research Datalink (CPRD)15  to investi-
gate the prevalence and predictors of previously 
described indicators8 10 12 13 in UK general practice. We 
measured the prevalence of indicators identifying 
patients at increased risk of a prescribing error during 
a time period leading up to 1 April 2013; examined the 
table 1 | definition of each prescribing safety indicator in general practice
id patients at risk of prescribing safety indicator (denominator) patients receiving prescribing safety indicator (numerator)
P1 Has asthma Read code at least 6 months before audit date and no asthma 
resolved code since latest asthma code
Had β blocker prescription within 6 months leading up to audit date
P2 Has asthma Read code at least 3 months before audit date and prescribed LABA 
inhaler within 3 months leading up to audit date
Not prescribed ICS or combined LABA-ICS within 3 months leading up to audit 
date
P3 Has Read code for peptic ulcer at least 6 months before audit date and not 
prescribed PPI, misoprostol, or H2 antagonist within 6 months leading up to audit 
date
Prescribed aspirin or clopidogrel within 6 months leading up to audit date
P4 Has Read code for peptic ulcer at least 6 months before audit date and not 
prescribed PPI, misoprostol, or H2 antagonist within 6 months leading up to audit 
date
Prescribed non-selective NSAID within 6 months leading up to audit date
P5 Has Read code for heart failure at least 3 months before audit date Prescribed glitazone within 3 months leading up to audit date
P6 Has Read code for heart failure at least 3 months before audit date Prescribed NSAID within 3 months leading up to audit date
P7 Has Read code for chronic kidney disease stage 3B, 4, or 5 at least 3 months 
before audit date 
Prescribed NSAID within 3 months leading up to audit date
P8 Has Read code for chronic kidney disease stage 4 or 5 at least 3 months before 
audit date
Prescribed metformin within 3 months leading up to audit date
P9 Has Read code for chronic kidney disease stage 3B, 4 or 5 at least 3 months before 
audit date
Prescribed digoxin at daily dose >125 µg within 3 months leading up to audit date
P10 Has a prescription for warfarin and not prescribed PPI, misoprostol or H2 
antagonist within 6 months leading up to audit date
Prescribed NSAID within 6 months leading up to audit date
P11 Has a prescription for warfarin and not prescribed PPI, misoprostol or H2 
antagonist within 6 months leading up to audit date
Prescribed aspirin within 6 months leading up to audit date
P12 Aged ≥65 on audit date and has Read code for dementia and no Read code for 
psychosis at least 6 months before audit date
Prescribed antipsychotics at least twice and 3 months apart within 6 months 
leading up to audit date
P13 Aged ≥65 on audit date and not prescribed PPI, misoprostol or H2 antagonist 
within 6 months leading up to audit date
Prescribed NSAID within 6 months leading up to audit date
P14 Has Read code for chronic kidney disease stage 3B, 4, or 5 and prescribed ACEI Prescribed NSAID within 3 months leading up to audit date
P15 Has Read code for chronic kidney disease stage 3B, 4, or 5 and prescribed ACEI 
and loop diuretic
Prescribed NSAID within 3 months leading up to audit date
P16 Female and has Read code for venous or arterial thrombosis at least 6 months 
before audit date
Prescribed CHC within 6 months leading up to audit date
P17 Female and Read code for BMI >40 between 66 and 6 months before audit date 
and without more recent Read code for BMI <40
Prescribed CHC within 6 months leading up to audit date
P18 Female, aged >35, and most recent Read code for smoking status is current 
smoker at least 6 months before audit date
Prescribed CHC within 6 months leading up to audit date
P19 Female and has Read code for breast cancer at least 6 months before audit date Prescribed oral or transdermal oestrogens within 6 months leading up to audit 
date
M1 Aged ≥75 and prescribed ACEI or loop diuretic 15-6 months before audit date and 
again within 6 months leading up to audit date
Have NOT had renal function or electrolytes test in 15 months leading up to audit 
date
M2 Prescribed amiodarone 6-12 months before audit date and again within 6 months 
leading up to audit date
Have NOT had thyroid function test in 6 months leading up to audit date
M3 Prescribed methotrexate 3-6 months before audit date and again within 3 months 
leading up to audit date
Have NOT had liver function test or full blood count in 3 months leading up to audit 
date
M4 Prescribed lithium 3-6 months before audit date and again within 3 months 
leading up to audit date
Have NOT had lithium level test in 3 months leading up to audit date
M5 Prescribed warfarin 3-6 months before audit date and again within 3 months 
leading up to audit date
Have NOT had INR check in 3 months leading up to audit date
ACEI=angiotensin converting enzyme inhibitor; BMI=body mass index; CHC=combined hormone contraceptive; ICS=inhaled corticosteroid; LABA=long acting β2 agonist; NSAID=non-steroidal 
anti-inflammatory drug (non-selective); PPI=proton pump inhibitor; INR=international normalised ratio.
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variation in the prevalence of the above indicators 
between practices using intraclass correlation coeffi-
cients and the meaning for the individual practice 
using reliability estimates; and examined the associa-
tions between the indicators and patient characteris-
tics (age, sex, number of repeat medications) and 
practice characteristics (list size, practice level depri-
vation, geographical location).
Methods
We included in the analysis all patients aged 18 or over 
who were registered with one of the CPRD practices 
that had uploaded data of research quality on or after 
1 April 2013. Each indicator consisted of a denomina-
tor and a numerator (table 1 ). The denominator 
included all patients with the potential to trigger an 
indicator because of an existing diagnosis or prescrib-
ing pattern (during a time period specific to the indica-
tor definition and the audit date, table 1 ). The 
numerator consisted of those patients who actually 
triggered the indicator by receiving the potentially 
unsafe prescription or having no record of the required 
monitoring during the time period leading up to the 
audit date (table 1. Therefore the prevalence of an indi-
cator describes the proportion of patients with the 
potential to trigger an indicator who actually did so. (A 
full list of codes to define each indicator has been 
uploaded to www.clinicalcodes.org.16 ) For the main 
analysis the prevalence of each indicator was mea-
sured relative to 1 April 2013 (the audit date), and the 
study is cross sectional at this date. In a further analy-
sis, however, we used a rolling time window of audit 
dates representing the 1st of the month from May to 
September 2013 to check whether the results were sen-
sitive to the choice of audit date. For long term condi-
tions, or a diagnosis associated with contraindicated 
prescribing, the cumulative number of patients since 
their first recorded diagnosis formed the denominator. 
For asthma diagnoses, patients were excluded from 
the denominator after an asthma resolved code but 
would return to the denominator if this were super-
seded by a new asthma diagnosis code (P1, table 1 , 
fig 1 ). When the condition or diagnosis was reversible, 
such as requiring monitoring with repeat prescrip-
tions, the denominator was the number of patients 
prescribed a repeat medication within a fixed time 
window before the audit date. For example, the 
denominator for repeat prescribing of angiotensin 
converting enzyme inhibitor (ACEI) or loop diuretic 
(M1, table 1 , fig 1) includes patients with at least one 
prescription of (ACEI) or loop diuretic between 6 and 
15 months before the audit date and a repeat prescrip-
tion between 0 and 6 months before the audit date. 
Polypharmacy was defined as the number of medica-
tions with at least two prescriptions within the 12 
months leading up to 1 April 2013.
Statistical methods
We calculated the proportion of patients triggering each 
indicator (with 95% confidence intervals from a bino-
mial distribution) for each indicator and for a compos-
ite prescribing (prescribing indicator, P1-P13) and 
monitoring (monitoring indicator, M1-M4) indicator. A 
further composite indicator also included the indicators 
relevant only to women in (P1-P13 plus P16-P19). Each 
patient counted just once in the composite indicator 
with a triggered indicator taking priority if a patient 
entered the denominator for more than one indicator. 
Therefore the composite indicator describes the num-
ber of patients triggering at least one indicator divided 
by all patients with the potential to trigger an indicator. 
The variation in prevalence between practices was 
quantified for each indicator by an empty mixed effects 
two level logistic regression model with patients nested 
within practices (using the xtmelogit command in 
Stata). The outcome was a binary variable (1 or 0) with 
patients triggering an indicator designated “1” and 
those with potential to trigger an indicator but not 
doing so designated “0.” We used the post-estimation 
estat command in Stata to derive the intraclass correla-
tion coefficients (ICCs) for each indicator. The intraclass 
correlation coefficient quantifies the proportion of the 
total variation in an indicator that is accounted for by 
the variation between practices (τ2)—that is, indicators 
with low values of intraclass correlation coefficient 
show that there is more variability within practices (σ2) 
rather than between them (τ2), in relation to the out-
come (fig 2).
The within-variance in this binary outcome context 
is non-intuitive and fixed in the logistic regression 
models, and it does not reflect variability in the 
Practices
Numerator
prescribed β blocker
1 April 2013
(audit date)Timeline
31 October 2013
(audit date minus
6 months)
More practices
up to standard by
31 October 2012
Example of long term diagnosis P1 asthma and prescribed β blocker
Example of short term condition M1 prescribed ACEI/loop diuretics and no U+E monitoring
31 October 2013
(audit date minus
6 months)
31 December 2011
(audit date minus
15 months)
9 months 6 months
Practices up
to standard by
31 December
2011
1 April 2013
(audit date)
Numerator - not had renal function or electrolyte test over 15 months
Denominator - at least one prescription
and at least one further prescription
Denominator unresolved
asthma diagnosis
Fig 1 | examples of indicator definitions
ICC = τ
2
τ2 + σ2
Fig 2 | Formula for proportion of total variation in indicator 
that is accounted for by variation between practices
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 performance of health professionals within a practice. 
Ideally, rather than being empty, the model would be 
adjusted by patient level variables reflecting the case 
mix before estimation of the intraclass correlation 
coefficient. As the adjusted model did not converge for 
some of the indicators, the empty model was the best 
option for consistency across all indicators. Adjust-
ment for age, sex, and polypharmacy did not alter the 
intraclass correlation coefficient for most of the indi-
cators where the model did converge. The intraclass 
correlation coefficient does not intuitively translate 
into an understanding of the implications for the indi-
vidual practice. Therefore, to help with interpretation 
of the ICC, we calculated the reliability for different 
numbers of patients in the denominator using the 
Spearman-Brown prophecy formula as described pre-
viously (fig 3) .9
For many situations a reliability of 0.7 is considered 
acceptable, but higher values might be preferable in 
comparisons of prescribing safety between practices.9 
We calculated the reliability for a hypothetical practice 
with the median number of patients in the denomina-
tor, and appendix 1 shows the number of practices with 
reliabilities greater than 0.7, 0.8, and 0.9. However, the 
intraclass correlation coefficient, and therefore reliabil-
ity, cannot provide insight on the underlying causes of 
the variation between practices that might, or might 
not, be clinical in nature. To further describe the hetero-
geneity between practices we also reported the preva-
lence predicted by the regression model for each 
indicator with 95% prediction intervals as described 
elsewhere.18 The prediction intervals describe the 
expected range of prevalence for a new practice (with 
95% confidence).
The composite indicators were further analysed with 
the same mixed effects two level logistic regression 
model. As described above each patient counted just 
once in this analysis with the outcome variable “1” des-
ignating patients triggering at least one indicator and 
“0” designating patients with the potential to trigger at 
least one indicator but not doing so. We analysed indi-
cators related to prescribing (prescribing indicators) 
separately from indicators related to monitoring (moni-
toring indicators). The practice level predictors were list 
size, intervals of the index of multiple deprivation (IMD) 
based on 2010 estimates,17 and location of practice by 
country or region of the UK. Patient level predictors 
were age, sex, and polypharmacy.
patient involvement
Given our specific aims, no patients were involved in 
setting the research question or the outcome measures, 
nor were they involved in the design and  implementation 
of the study. We will be working with the Research User 
Group at the NIHR Greater Manchester Primary Care 
Patient Safety Translational Research Centre to advise 
on plans for dissemination of these findings.
Results
Data were available from 526 practices and almost five 
million patients. The mean list size between 1 April 
2012 and 31 March 2013 was 9410 (standard deviation 
4971). Most practices were in England (384, 73%), fol-
lowed by Scotland (72, 14%), Wales (49, 9%), and 
Northern  Ireland (21, 4%). More details on the 
make-up of the CPRD practices and their representa-
tiveness of the UK primary care have been provided 
elsewhere.19
The choice of audit date did not greatly affect the 
prevalence of the indicator (comparing audit date 1 
April 2013 with a rolling time window 1 May-1 Septem-
ber 2013) except for M4 (prescription of lithium with-
out a lithium level test). The lower prevalence when 
we used the 1 April audit date was because of an 
increased frequency of lithium level tests during Janu-
ary 2013. Analysis that used earlier audit dates showed 
that the January increase in tests occurred every year 
as far back as 2005 (data available from authors).
Tables 2  and 3  and figure 4  summarise the observed 
prevalence, predicted prevalence, and ICC for each 
indicator and the composite indicators. The distribu-
tion of the observed prevalence for each indicator by 
practices and by list size is summarised in appendix 1. 
The prevalence of the monitoring indicators was consis-
tently higher than prescribing indicators (fig 4 ). The 
prescribing indicators with a higher prevalence were 
mainly those related to the prescribing of NSAIDs and 
aspirin without gastroprotection (P3-P4, P11, P13, fig 4 ), 
whereas the prescribing of combined hormone contra-
ceptives (CHC) and oestrogens was associated with a 
lower prevalence (P16-P19, fig 4).
Overall, 49 927 of 949 552 (5.26%, 95% confidence 
interval 5.21% to 5.30%; table 2 ) patients triggered at 
least one prescribing indicator (P1-13). We excluded two 
indicators from the prescribing composite indicator (P1-
P13, table 2 ) as they were nested within P7 and dealt 
with subgroup populations (P14-P15). Four were 
excluded because they were relevant only to women 
(P16-P19) and we wanted to evaluate the relation 
between sex and overall risk in a set of indicators that 
was relevant across both sexes. An alternative compos-
ite indicator included the indicators relevant to women 
(P1-P13 and P16-P19) and was triggered by 52 671 of 
1 195 408 patients (4.41%, 4.37% to 4.44%; table 2 ).The 
corresponding composite monitoring indicator (M1-M4 
excluding M5) was triggered by 21 501 of 182 721 patients 
(11.8%, 11.6% to 11.9%) (table 3 ). The decision to 
exclude M5 (warfarin without international normalised 
ratio (INR) testing) from the composite monitoring indi-
cator was based on the large variation between prac-
tices (ICC=0.78) that was judged to reflect INR results 
not being recorded in CPRD (possibly because of differ-
ent models of service delivery20 ) rather than real 
 differences in INR testing. Previous work found that INR 
tests might be recorded in secondary, rather than pri-
mary, care records.21
Reliability =
 number of patients in denominator  *  ICC
1 + (number of patients in denominator – 1)  *  ICC
Fig 3 | Spearman-Brown prophecy formula
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Most patients triggered just one indicator (48 504 
(97.1%), prescribing indicator; 21 399 (99.5%), moni-
toring indicator), but a few triggered two indicators 
(1253 (2.5%) prescribing indicator; 102 (0.5%) moni-
toring indicator) and 170 (0. 3%) patients triggered 
three or more prescribing indicator. Many practices 
had a prevalence of prescribing indicators over the 
90th centile for just one prescribing indicator (158 
(30%), P1-P13), but some practices were repeatedly 
over the 90th centile for different prescribing indica-
tor; 100 (19%) practices were over the 90th centile 
twice, 79 (15%) three to four times, and 10 (2%) five to 
six times. For monitoring indicators, 166 (32%, M1-M4) 
practices had a prevalence over the 90th centile for 
just one indicator, 29 (6%) twice, and six (1%) three to 
four times. Monitoring indicators had larger ICCs than 
prescribing indicators; 0.17 (0.15 to 0.19) for the com-
posite monitoring indicator and 0.04 (0.03 to 0.05) for 
the composite prescribing indicator (table 2 , fig 4 ). 
There was low between-practice variation in prescrib-
ing β blockers to patients with asthma (ICC P1: 0.03, 
0.02 to 0.04), aspirin to patients with peptic ulcer 
without gastroprotection (ICC P3: 0.04, 0.02 to 0.06), 
or co-prescription of warfarin and aspirin without 
gastroprotection (ICC P11: 0.03, 0.02 to 0.04) (table 2 , 
fig 4 ). The reliability provides guidance about how 
confidently we can compare an individual practice 
with a known number of denominator patients with 
the prevalence over all practices. The implication is 
that for an indicator with lower ICC, higher numbers 
of denominator patients are required for a reliable 
comparison. For this reason, although the indicator 
related to prescribing β blockers to patients with 
asthma (P1) has a low ICC, the reliability is high 
because of the large denominator (number of patients 
diagnosed with asthma, table 2 ). Conversely prescrib-
ing amiodarone without a thyroid function test (M2) 
has a higher ICC but the small denominator (number 
of patients prescribed amiodarone) means that the 
reliability is low (table 3).
Tables 4  and 5  show the prevalence of patients trig-
gering at least one prescribing indicator or monitoring 
indicator (composite indicators) by characteristics of 
patients and practices, as well as unadjusted and 
adjusted odds ratios derived from the multilevel mixed 
effects logistic regression model. Polypharmacy was 
strongly associated with increased risk of triggering 
the composite prescribing indicator (1.3% of patients 
with zero or one repeat medication  compared with 
table 3 | Summary of prevalence and variation between practices for each monitoring safety indicator
indicator and (short) 
description
numerator/ denominator 
(1 april 2013)
observed 
prevalence (95% Ci) iCC* (95% Ci) rel†
predicted prevalence  
(95% prediction intervals)‡
prevalence (95% Ci)  
1 May-1 Sept
M1: aged 75 and ACEI or 
loop diuretic without U+E 
monitoring
17 092/164 630 10.4% (10.2 to 10.5) 0.21 (0.19 to 0.24) 0.99 8.3% (1.4 to 36.8) 10.9% (10.9 to 11.0)
M2: repeat amiodarone 
without TFT
1596/3809 41.9% (40.3 to 43.5) 0.13 (0.10 to 0.17) 0.47 41.5% (15.2 to 73.7) 42.2% (41.6 to 42.9)
M3: repeat methotrexate 
without LFT or FBC
2117/13 231 16.0% (15.4 to 16.6) 0.41 (0.36 to 0.45) 0.94 11.1% (0.6 to 70.5) 16.7% (16.4 to 17.0)
M4: repeat lithium without 
lithium concentration check
798/4126 19.3% (18.2 to 20.6) 0.12 (0.08 to 0.17) 0.49 17.5% (5.4 to 44.3) 33.9% (33.3 to 34.5)
M5: repeat warfarin without 
INR
16 463/51 008 32.3% (31.9 to 32.7) 0.78 (0.75 to 0.80) 1.00 19.6% (0.0 to 99.5) 32.4% (32.2 to 32.6)
M1-M4: at least one 
monitoring indicator
21 501/182 721 11.8% (11.6 to 11.9) 0.17 (0.15 to 0.19) 0.98 10.2% (2.2 to 36.0) 11.7% (11.6 to 11.7)
ACEI=angiotensin converting enzyme inhibitor; U+E=urea and electrolyte monitoring; FBC=full blood count; INR=international normalised ratio; TFT=thyroid function test; LFT=liver function test.
*Intraclass correlation coefficient.
†Reliability for practice with median number of patients at risk of triggering indicator.
‡Predicted prevalence in new practice with 95% prediction intervals using logistic regression model.
Intraclass correlation coecient
with 95% condence intervals
P1. Asthma/β blockers
P2. Asthma/LABA inhaler no ICS
P3. Peptic ulcer/aspirin
P4. Peptic ulcer/NSAID
P5. Heart failure/glitazone
P6. Heart failure/NSAID
P7. CKD/NSAID
P8. CKD/metformin
P9. CKD/digoxin
P10. Warfarin/NSAID
P11. Warfarin/aspirin
P12. Dementia/antipsychotics
P13. Over 65/NSAID
P14. CKD/ACEI/NSAID
P15. CKD/ACEI/loop diuretic/NSAID
P16. Thrombosis/CHC
P17. BMI ≥40/CHC
P18. Current smoker/CHC
P19. Breast cancer/oestrogens
M1. ACEI/loop diuretic no U&E
M2. Amiodarone no TFT
M3. Methotrexate no LFT or FBC
M4. Lithium no lithium level check
M5. Warfarin no INR
P1-P13. Composite prescribing
P1-P12. Composite prescribing
M1-M4. Composite monitoring indicator
0 0.2 0.4 0.6 0.8 1.0
Prevalence of indicator (%)
with 95% condence intervals
0 10 20 30 40 50
Fig 4 | prevalence and intraclass correlation coefficients for individual and composite 
indicators of potentially hazardous prescribing in general practice
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12.1% of patients with 11 or more long term medica-
tions, table 4 ). The opposite was observed for the com-
posite monitoring indicator where increasing repeat 
medications was associated with decreased risk 
(25.7% of patients with zero or one repeat  medication 
compared with 8.8% of patients with 11 or more long 
term medications, table 5 ). Increasing age was associ-
ated with increasing prevalence of the composite pre-
scribing indicator (1.5% for patients aged ≤50 
compared with 7.0% for patients aged 71-80; table 4 ), 
though there was a protective effect for the oldest 
patients (4.6% for patients aged >80; table 4 ). Again 
the opposite trend was observed for the composite 
monitoring indicator as prevalence decreased with age 
(22.1% for patients aged ≤50 compared with 10.2% for 
patients aged 71-80; table 5 ). Women were more likely 
to trigger a monitoring indicator (12.4% compared with 
10.8% in men; table 5 ) but less likely to trigger a pre-
scribing indicator (5.1% compared with 5.5% in men; 
table 4 ). Practice level variables had much less influ-
ence than patient level variables; there was no effect of 
list size on composite prescribing or monitoring indi-
cators. Practice level index of multiple deprivation 
showed a small significantly increased prevalence for 
the composite prescribing indicator for practices in 
more deprived areas in the unadjusted model (table 
4 ). For the composite monitoring indicator there was 
no significant association with practice level index of 
multiple deprivation in the unadjusted model but the 
adjusted model showed small significant increases for 
the practices above the third quintile and below the 
fifth quintile but not the most deprived (above the fifth 
table 4 | prevalence of patients receiving at least one high risk prescribing indicator and multilevel unadjusted and 
adjusted odds ratios (p1 to p13)
Variable (no at risk)
% prevalence 
(95% Ci)
odds ratio (95% Ci)
unadjusted adjusted
Age (years):
 18-50 (197 180) 1.5 (1.4 to 1.6) 1 1
 51-60 (54 147) 4.9 (4.7 to 5.1) 3.28 (3.11 to 3.46) 1.95 (1.84 to 2.01)
 61-70 (227 961) 7.2 (7.1 to 7.4) 5.20 (5.00 to 5.41) 3.57 (3.43 to 3.72)
 71-80 (257 528) 7.0 (6.9 to 7.1) 4.98 (4.79 to 5.18) 2.84 (2.72 to 2.96)
 >80 (212 736) 4.6 (4.5 to 4.7) 3.39 (3.26 to 3.54) 1.71 (1.64 to 1.78)
No of drugs on repeat prescription in past 12 months:
 0-1 (344 254) 1.3 (1.2 to 1.4) 1 1
 2-4 (234 715) 4.8 (4.7 to 4.9) 3.70 (3.58 to 3.84) 3.39 (3.27 to 3.51)
 5-7 (161 580) 7.1 (7.0 to 7.2) 5.64 (5.45 to 5.84) 4.99 (4.81 to 5.17)
 8-10 (96 100) 9.4 (9.3 to 9.6) 7.71 (7.43 to 8.00) 6.95 (6.70 to 7.22)
 >10 (112 903) 12.0 (11. 9 to 12.3) 10.17 (9.82 to 10.53) 9.40 (9.07 to 9.74)
Sex (18 missing):
 Male (431 280) 5.5 (5.4 to 5.6) 1 1
 Female (518 254) 5.1 (5.0 to 5.2) 0.93 (0.91 to 0.95) 0.92 (0.90 to 0.93)
List size (fourths):
 <5700 (99 426) 5.5 (5.4 to 5.7) 1 1
 5701-8600 (183 403) 5.8 (5.6 to 5.9) 1.05 (0.95 to 1.15) 1.03 (0.95 to 1.13)
 8601-12 100 (265 806) 5.4 (5.3 to 5.5) 0.97 (0.88 to 1.07) 1.00 (0.92 to 1.09)
 >12 100 (400 917) 4.9 (4.8 to 5.0) 0.90 (0.81 to 0.99) 0.99 (0.91 to 1.08)
Practice level index of multiple deprivation:
 1 least deprived (192 176) 5.0 (4.9 to 5.1) 1 1
 2 (190 625) 5.0 (4.9 to 5.2) 1.04 (0.93 to 1.17) 1.00 (0.91 to 1.10)
 3 (199 197) 5. 5 (5.4 to 5.6) 1.14 (1.01 to 1.27) 1.07 (0.97 to 1.18)
 4 (195 128) 5.4 (5.3 to 5.5) 1.14 (1.02 to 1.28) 1.03 (0.94 to 1.14)
 5 most deprived (172 426) 5.5 (5.4 to 5.6) 1.14 (1.02 to 1.28) 1.01 (0.92 to 1.12)
Region:
 North West (113 105) 5.9 (5.7 to 6.0) 1 1
 North East (14 527) 5.0 (4.6 to 5.3) 0.75 (0.56 to 1.00) 0.76 (0.59 to 0.99)
 Yorkshire/Humber (10 988) 7.9 (7.4 to 8.5) 1.34 (0.96 to 1.87) 1.35 (1.00 to 1.83)
 East Midlands (6040) 5.0 (4.5 to 5.6) 0.81 (0.52 to 1.24) 0.81 (0.55 to 1.20)
 West Midlands (89 358) 5.3 (5.1 to 5.4) 0.89 (0.77 to 1.03) 0.90 (0.79 to 1.02)
 East of England (69 486) 4.9 (4.7 to 5.0) 0.80 (0.68 to 0.94) 0.89 (0.77 to 1.03)
 South West (95 920) 5.0 (4.8 to 5.1) 0.80 (0.69 to 0.93) 0.83 (0.73 to 0.95)
 South Central (119 249) 5.1 (5.0 to 5.2) 0.84 (0.73 to 0.96) 0.94 (0.83 to 1.07)
 London (101 801) 4.3 (4.2 to 4.4) 0.69 (0.61 to 0.78) 0.77 (0.69 to 0.87)
 South East coast (108 655) 4.8 (4.6 to 4. 9) 0.78 (0.68 to 0.89) 0.86 (0.76 to 0.97)
 Northern Ireland (28 924) 7.5 (7.2 to 7.8) 1.26 (1.05 to 1.52) 1.15 (0.97 to 1.36)
 Scotland (99 912) 5.5 (5.3 to 5.6) 0.92 (0.81 to 1.04) 0.92 (0.82 to 1.04)
 Wales (91 587) 5.7 (5.6 to 5. 9) 0.97 (0.85 to 1.12) 0.90 (0.79 to 1.02)
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quintile (table 5 ). Northern Ireland had a significantly 
higher prevalence for the composite prescribing indi-
cator relative to all other regions in the unadjusted 
model, and some regions in England were significantly 
lower (East of England, South Central, London, South 
West, South East Coast); none remained significant in 
the adjusted model (table 4 ). For the composite moni-
toring indicator North East England had significantly 
lower prevalence whereas South Central and London 
were significantly higher (table 5).
We excluded the indicators relevant only to women 
from the composite prescribing indicator (P1-P13) to 
allow meaningful comparisons between sexes; how-
ever, this is not to say that the indicators relevant to 
women are less important. Table A in appendix 2 
shows the odds ratios derived from the multilevel 
mixed effects logistic regression model for the 
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Fig 5 | prevalence of composite prescribing and monitoring indicators in individual 
practices ranked by prescribing indicators
table 5 | prevalence of patients receiving at least one high risk monitoring indicator and multilevel unadjusted and 
adjusted odds ratios (M1 to M4)
Variable (no at risk)
% prevalence 
(95% Ci)
odds ratio (95% Ci)
unadjusted adjusted
Age (years):
 18-50 (3979) 22.1 (20.9 to 23.4) 1 1
 51-60 (4070) 19.9 (18.8 to 21.1) 0.84 (0.75 to 0.94) 0.92 (0.82 to 1.04)
 61-70 (5317) 19.0 (18.0 to 20.1) 0.80 (0.72 to 0.89) 0.97 (0.87 to 1.08)
 71-80 (67 538) 10.2 (10.0 to 10.5) 0.36 (0.33 to 0.39) 0.44 (0.40 to 0.48)
 >80 (101 817) 11.7 (11.5 to 11.9) 0.42 (0.39 to 0.46) 0.53 (0.49 to 0.58)
No of drugs on repeat prescription in past 12 months:
 0-1 (10 490) 25.7 (23.5 to 28.1) 1 1
 2-4 (23 404) 18.3 (17.9 to 18.8) 0.64 (0.56 to 0.72) 0.68 (0.60 to 0.78)
 5-7 (43 957) 13.3 (12.9 to 13.6) 0.42 (0.37 to 0.48) 0.47 (0.41 to 0.53)
 8-10 (40 993) 10.7 (10.4 to 11.0) 0.33 (0.29 to 0.37) 0.36 (0.32 to 0.42)
 >10 (63877) 8.8 (8.6 to 9.0) 0.26 (0.23 to 0.30) 0.29 (0.25 to 0.33)
Sex:
 Male (75 210) 10.8 (10.6 to 11.1) 1 1
 Female (107 511) 12.4 (12.2 to 12.6) 1.17 (1.13 to 1.20) 1.16 (1.12 to 1.20)
List size (fourths):
 <5700 (20 378) 13.3 (12.8 to 13.8) 1 1
 5701-8600 (36 770) 12.1 (11.8 to 12.5) 0.97 (0.79 to 1.19) 0.97 (0.79 to 1.19)
 8601-12 100 (52 639) 11.6 (11.4 to 11.9) 0.93 (0.76 to 1.15) 0.90 (0.73 to 1.11)
 >12 100 (72 934) 11.2 (11.0 to 11.5) 0.93 (0.76 to 1.15) 0.95 (0.77 to 1.18)
Practice level index of multiple deprivation:
 1 least deprived (34 890) 10.8 (10.5 to 11.2) 1 1
 2 (39 087) 11.9 (11.6 to 12.3) 1.16 (0.91 to 1.46) 1.14 (0.90 to 1.44)
 3 (39 699) 12.3 (12.0 to 12.6) 1.25 (0.99 to 1.58) 1.37 (1.09 to 1.73)
 4 (37 944) 12.3 (11.9 to 12.6) 1.25 (0.99 to 1.58) 1.32 (1.04 to 1.67)
 5 most deprived (31 101) 11.3 (11.0 to 11.7) 1.11 (0.88 to 1.41) 1.27 (0.99 to 1.62)
Region:
 North West (20 587) 10.6 (10.2 to 11.1) 1 1
 North East (2744) 5.8 (5.0 to 6.8) 0.43 (0.22 to 0.82) 0.43 (0.22 to 0.83)
 Yorkshire/Humber (1975) 12.5 (11.1 to 14.0) 1.40 (0.67 to 2.89) 1.38 (0.66 to 2.88)
 East Midlands (1204) 13.9 (12.0 to 15.9) 0.93 (0.36 to 2.37) 0.95 (0.37 to 2.47)
 West Midlands (17 801) 10.8 (10.3 to 11.2) 1.09 (0.80 to 1.49) 1.10 (0.81 to 1.50)
 East of England (12 761) 10.8 (10.3 to 11.4) 1.08 (0.77 to 1.53) 1.08 (0.76 to 1.54)
 South West (18 662) 8.4 (8.0 to 8.8) 0.75 (0.55 to 1.02) 0.70 (0.51 to 0.96)
 South Central (22 679) 14.0 (13.6 to 14.5) 1.37 (1.02 to 1.84) 1.37 (1.00 to 1.86)
 London (18 328) 14.6 (14.0 to 15.0) 1.52 (1.16 to 1.99) 1.47 (1.11 to 1.94)
 South East Coast (22 230) 12.0 (11.6 to 12.5) 1.23 (0.92 to 1.64) 1.17 (0.87 to 1.57)
 Northern Ireland (6276) 10.2 (9.5 to 11.0) 1.01 (0.68 to 1.51) 1.03 (0.68 to 1.56)
 Scotland (19 365) 14.4 (14.0 to 14.9) 1.16 (0.88 to 1.54) 1.14 (0.86 to 1.51)
 Wales (18 109) 10.6 (10.2 to 11.0) 0.89 (0.66 to 1.21) 0.89 (0.65 to 1.20)
the bmj | BMJ   2015;101h1120 | doi1 02.00;6/bmj.h1120
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 composite prescribing indicator that included the 
indicators for women (P1-P13 plus P16-P19). There 
were few differences between the predictors for these 
two composite prescribing indicators (P1-P13 v P1-P13 
plus P16-P19) except, as expected, on sex and age (as 
a result of combined hormone contraceptive pre-
scribing occurring mostly in the younger age group). 
Additionally as both composite prescribing and mon-
itoring indicators included a single indicator with a 
large denominator that could have driven the obser-
vations, we ran the model separately for P1-P12 and 
P13 (the indicator related to prescribing NSAID to a 
patient aged >65) and M1 (the indicator related to pre-
scribing angiotensin converting enzyme inhibitor 
without urea and electrolyte tests) and M2-M4. Tables 
B-E in appendix 2 show the results. For the composite 
prescribing indicator the effect size of polypharmacy 
in the adjusted model was driven largely by P1-P12. 
The likelihood of triggering P13 (patients aged >65 
prescribed NSAIDs) increased with two to four 
repeated prescriptions but did not increase further 
with increasing number of prescriptions (table B and 
C in appendix 2). For the monitoring indicator, the 
composite was strongly influenced by M1: exclusion 
of M1 from the composite (M2-M4) reversed the direc-
tion of sex, with women becoming less likely to trig-
ger the composite monitoring indicator (tables D and 
E in appendix 2). Furthermore, the decrease in preva-
lence with increasing repeat medications occurred in 
the two to four repeated prescriptions group and did 
not increase further with increasing number of 
 prescriptions.
Figure 5 shows the prevalence of composite prescrib-
ing and monitoring indicators for each practice. A high 
prevalence for the composite prescribing indicator does 
not predict a high prevalence for the composite moni-
toring indicator or vice versa.
discussion
principal findings
There is a high variation in prevalence between gen-
eral practices for indicators of potentially hazardous 
prescribing and missed monitoring tests. It is unlikely 
that variation in case mix could explain the large dif-
ferences between practices, though prescribing indi-
cators can occur for valid clinical reasons. There is no 
parallel argument that a monitoring indicator might 
occur for clinical reasons but patient behaviour might 
be an important factor. Furthermore, monitoring indi-
cators can occur because of poor recording of test 
results, whereas most prescribing is systematically 
recorded through the electronic prescribing system 
and is known to be accurate (reflected in the larger 
intraclass correlation coefficients (ICC) for monitoring 
indicators).22 Many practices, however, do have zero 
prevalence for some indicators, and these results 
might help to set reasonable expectations for individ-
ual practices.
An important question is whether or not it is appro-
priate to use these indicators to compare prescribing 
safety between practices. The ICC suggests that the 
differences between practices are an important source 
of variation in the prevalence of the indicators, espe-
cially for monitoring indicators, but the ICC is a statis-
tical concept and further work is needed to estimate 
how often indicators result from oversight or error 
rather than a clinical decision. The reliability esti-
mates (derived from the ICC) show that some practices 
have insufficient numbers of patients in the denomi-
nator for reliable prevalence estimates for some indi-
cators and these practices should not be compared 
with other practices. For the composite indicators, 
however, the reliability was good across all practices 
(>0.8, appendix 1), suggesting that comparisons 
between all practices should focus on the composite 
indicators.
High levels of variation between practices might also 
reflect differences in service organisation—for example, 
M5 (prescribed warfarin and no INR) has an ICC of 0.78, 
possibly because in some practices that prescribe war-
farin the INR results might be recorded outside the 
practice electronic record system and are not uploaded 
to CPRD.20 21 One way to identify practices with high risk 
prescribing might be to look for those with a consis-
tently higher prevalence across several different indica-
tors; 17% of practices had prevalence over the 90th 
centile for three or more of the 13 prescribing indicators 
(P1-P13) and 7% of practices for two or more of the four 
monitoring indicators (M1-M4).
If a lower prevalence of these indicators is a mea-
sure of good practice then we would expect consis-
tency between prescribing and monitoring indicators 
within practices. An alternative hypothesis is that 
since prescribing indicators are the culmination of a 
series of actions, whereas monitoring indicators result 
from inaction on the part of the practice or the patient, 
practices with a lower prevalence of monitoring indi-
cators would have a higher prevalence of prescribing 
indicators. In fact there was no clear relation between 
the two types of indicator within practices (fig 5). 
There were differences, however, in the type of patient 
triggering prescribing or monitoring indicators. Older 
patients and those receiving multiple repeat prescrip-
tions had the highest risk of triggering the composite 
prescribing indicator, whereas younger patients with 
fewer repeat prescriptions had a higher risk of trigger-
ing the composite monitoring indicator. The implica-
tion is that different types of intervention might 
be  required to deal with the two types of high risk 
 prescribing.
Practice level variables had much smaller effects 
than patient level variables; patients attending prac-
tices in more deprived areas were more likely to trig-
ger the composite prescribing indicator, possibly 
reflecting more prescribing within the practice lead-
ing to higher potential for a prescribing indicator. For 
the composite monitoring indicator, however, modest 
significant effects of practice level deprivation were 
seen only in the adjusted model, suggesting that 
patients attending practices in deprived areas have no 
increased likelihood of missing monitoring tests. The 
definition of the composite prescribing indicator did 
doi1 02.00;6/bmj.h1120 | BMJ   2015;101h1120 | the bmj
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not substantially alter the predictions made by the 
model but M1 (prescribing ACEI without urea and 
electrolyte monitoring) was the major driver for a 
monitoring indicator and, given the number of 
patients at risk, might be a better marker of prescrib-
ing safety.
In this group of 526 practices, about 5% of patients 
with the potential to trigger a prescribing indicator 
did so and about 12% triggered a monitoring indica-
tor. Whether or not these prevalence estimates might 
be generalised to the UK depends on how representa-
tive the practices participating in CPRD are in terms of 
characteristics of patients and practices. Practices in 
CPRD are slightly larger than the UK average (this 
might not cause bias as list size was not a significant 
predictor of prevalence) but are representative in 
terms of patient level deprivation and ethnicity.23  All 
CPRD practices in this study use Vision software to 
manage their patient data, and the choice of software 
has been associated with differences in recorded clin-
ical data.24  The regional differences in the choice of 
software impact on the geographical representative-
ness of CPRD; Yorkshire, Humberside, and North East 
England are under-represented.23 Given this, it is reas-
suring that there are few regional differences in the 
prevalence of the indicator. The lower prevalence of 
monitoring indicator in the North East and higher 
prevalence in London might simply reflect selection 
bias given the small number of practices. While there 
might be an argument for generalising these preva-
lence estimates to the UK, we need to be more cau-
tious in making the same case for the reliability 
estimates. The variability between practices, from 
which both the ICC and reliability are derived, might 
be specific to this group of practices and hence a gen-
eralisation to the whole of the UK primary care might 
be difficult to justify.
Comparison with other studies
It is useful to compare these findings with studies in 
other UK practices. Consideration, however, must be 
given to the date of analysis as the quality of elec-
tronic data has improved over recent years. The audit 
date chosen here is a compromise between being as 
recent as possible but also allowing time for most 
practices to have had their data uploaded. The preva-
lence of these indicators was not sensitive to the 
choice of audit date, suggesting that seasonality and 
the Quality Outcomes Framework (QOF) return date 
had little impact. (The QOF incentive scheme pro-
vides UK GPs with financial incentives related to per-
formance indicators and practices can review their 
patient records before the annual return in April19 ). 
The only exception was M4 (prescribed lithium with-
out lithium level check), where the increase in lithium 
level tests during January might relate to preparation 
for the QOF return or the end of the financial year. The 
PINCER trial found similar prevalences for P1, P4, 
P16, M1, and M2 (using identical definitions) in 72 
practices in Nottinghamshire, Staffordshire, and 
Cheshire during 2006-07.10  There were, however, 
some differences; the prevalence for M3 (methotrex-
ate without full blood count or liver function test) was 
35-42% in the PINCER trial but 16% in the CPRD; and 
for M5 (warfarin and INR) 6-7% in PINCER and 32% in 
the CPRD. (CPRD data might not capture all INR test 
results as discussed above, whereas the PINCER trial 
excluded practices that were known to undertake 
their own INR monitoring from this indicator). A 
study of 315 practices in Scotland used different indi-
cator definitions measured relative to 31 March 2007; 
there were similar findings for the comparable indica-
tors.9  The prescription of gastroprotectants, however, 
was treated differently. We excluded patients from the 
denominator if they had been prescribed gastropro-
tection, whereas the Scottish indicator excluded them 
from the numerator.9 If the same definition as the 
Scottish indicator for prescribing NSAIDS to elderly 
patients was applied, the prevalence was similar 
between the two datasets (data available from 
authors).
limitations of the study
While it is relatively straight forward for GPs within the 
UK to compare their practice with these results, it is a 
weakness of this study that international comparisons 
with these data would be challenging. Such compari-
sons would require access to routinely collected patient 
data (even CPRD might be missing some data—for 
example, INR tests20 21). In many countries healthcare 
data are collected primarily for payment or insurance 
purposes and the clinical utility of the indicators, and 
their representativeness of the general population, 
might be uncertain.
Conclusions and policy implications
These results emphasise the need to give due consid-
eration to the risks of prescribing multiple medica-
tions and the importance of regular medication 
reviews, especially for patients with multiple morbid-
ity. Here we provide a baseline prevalence from which 
to determine whether or not prescribing safety is 
improving.
These findings are also relevant to policy makers 
looking for ways to compare and potentially reward 
practices with respect to prescribing safety, although 
careful consideration needs to be given to any such 
 initiative. Prescribing tends to be an individual 
rather than practice responsibility and prescriptions 
might be initiated in secondary care rather than by 
the GP. Further work would also be needed to esti-
mate clearly how frequently indicators result from a 
clinical decision rather than an oversight or error 
and which indicators pose the most risk to the 
patient.
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